Jodascan Injection contains Iohexol 755 mg/ml, a non-ionic, water-soluble radiographic contrast agent used primarily for enhancing imaging quality in diagnostic radiology. Iohexol works by increasing the contrast of structures or fluids within the body during X-ray-based imaging procedures, including computed tomography (CT) scans, angiography, urography, and myelography. Its low osmolality compared to older contrast agents reduces the risk of adverse reactions, making it suitable for patients requiring enhanced visualization of vascular, urinary, or gastrointestinal systems. Jodascan Injection is administered intravenously or via other routes depending on the diagnostic requirement, under strict medical supervision. Prior to administration, patient history should be reviewed for hypersensitivity to iodinated contrast media, renal impairment, or thyroid disorders, as these conditions may increase the risk of complications. Adequate hydration before and after the procedure is recommended to facilitate renal clearance of the agent and minimize nephrotoxicity. Common adverse effects include mild nausea, warmth sensation, or transient headache, while severe reactions such as anaphylaxis are rare but require immediate medical intervention. Jodascan Injection should be used cautiously in patients with pre-existing renal dysfunction or cardiovascular instability. Proper dosing and administration protocols must be followed to ensure diagnostic efficacy and patient safety.